Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs CDX 301 (Primary) ; Gp100 MART-1 tyrosinase peptides vaccine
- Indications Malignant melanoma; Renal cancer
- Focus Therapeutic Use
- 10 Jul 2013 New trial record
- 20 Jun 2013 Biomarkers information updated